HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs

Objective: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are a global public health problem. Biological drugs can cause reactivation of HBV infection in patients with chronic HBV carrier or occult HBV infection. Likewise, it is known that it can cause reactivation of HCV infection...

Full description

Bibliographic Details
Main Authors: Mehmet Ali Balcı, Nazım Ekin
Format: Article
Language:English
Published: Dicle University Medical School 2020-12-01
Series:Dicle Medical Journal
Subjects:
Online Access:http://diclemedj.org/upload/sayi/79/Dicle%20Med%20J-04421.pdf
id doaj-931b2140cd52428880c17137b8d1d290
record_format Article
spelling doaj-931b2140cd52428880c17137b8d1d2902021-01-01T10:23:49ZengDicle University Medical SchoolDicle Medical Journal 1300-29451308-98892020-12-0147494795310.5798/dicletip.850523HBV and HCV Seroprevalence in Rheumatology Patients Using Biological DrugsMehmet Ali Balcı0https://orcid.org/0000-0003-0597-7788Nazım Ekin1https://orcid.org/0000-0001-5302-8953Romatoloji Uzmanı, İç Hastalıkları Romatoloji Kliniği, S.B.Ü Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Diyarbakır, TürkiyeGastroenteroloji Uzmanı, İç Hastalıkları Gastroenteroloji Kliniği, S.B.Ü Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Diyarbakır, TürkiyeObjective: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are a global public health problem. Biological drugs can cause reactivation of HBV infection in patients with chronic HBV carrier or occult HBV infection. Likewise, it is known that it can cause reactivation of HCV infection in patients who are positive for Anti HCV. In our study, we aimed to investigate the prevalence of HBV and HCV infections in rheumatology patients receiving biological therapy. Method: 582 patients who applied to Diyarbakır Health Sciences University Gazi Yaşargil Training and Research Hospital Rheumatology Polyclinic between 01/09/2017 and 01/09/2020 and using biological treatment were included in the study. Demographic and laboratory characteristics were recorded retrospectively. Statistical analysis was performed with SPSS V22.0 (IBM SPSS Statistics, Armonk, NY) software. Results: A total of 582 patients, 342 (58.8%) female and 240 (41.2%) male, were included in our study. Of the patients included in the study, 290 (49.8%) were diagnosed with ankylosing spondylitis (AS), 213 (36.6%) rheumatoid arthritis (RA), and 23 (4%) psoriatic arthritis (PsA). HBsAg 1.4%, Anti-HBs 51.7%, Anti-HBc IgG 31.4% and Anti-HCV 0.3% were positive. Looking according to the diagnosis; In AS; HBsAg 1.7%, Anti-HBs 53.1%, Anti-HBc IgG 38.9%, Anti-HCV 0.0%, in RA; HBsAg was 1.4%, Anti-HBs 51.9%, Anti-HBc IgG 41.7%, Anti-HCV 0.5% were detected. Conclusion: In our country, HBV and HCV infections are still seen at medium endemic levels. Since biological treatments may cause reactivation of HBV and HCV infections, screening, prophylaxis and treatment of these infections before biological treatment still maintains its importance.http://diclemedj.org/upload/sayi/79/Dicle%20Med%20J-04421.pdfhepatitis bhepatitis cbiological therapy.
collection DOAJ
language English
format Article
sources DOAJ
author Mehmet Ali Balcı
Nazım Ekin
spellingShingle Mehmet Ali Balcı
Nazım Ekin
HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
Dicle Medical Journal
hepatitis b
hepatitis c
biological therapy.
author_facet Mehmet Ali Balcı
Nazım Ekin
author_sort Mehmet Ali Balcı
title HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
title_short HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
title_full HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
title_fullStr HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
title_full_unstemmed HBV and HCV Seroprevalence in Rheumatology Patients Using Biological Drugs
title_sort hbv and hcv seroprevalence in rheumatology patients using biological drugs
publisher Dicle University Medical School
series Dicle Medical Journal
issn 1300-2945
1308-9889
publishDate 2020-12-01
description Objective: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are a global public health problem. Biological drugs can cause reactivation of HBV infection in patients with chronic HBV carrier or occult HBV infection. Likewise, it is known that it can cause reactivation of HCV infection in patients who are positive for Anti HCV. In our study, we aimed to investigate the prevalence of HBV and HCV infections in rheumatology patients receiving biological therapy. Method: 582 patients who applied to Diyarbakır Health Sciences University Gazi Yaşargil Training and Research Hospital Rheumatology Polyclinic between 01/09/2017 and 01/09/2020 and using biological treatment were included in the study. Demographic and laboratory characteristics were recorded retrospectively. Statistical analysis was performed with SPSS V22.0 (IBM SPSS Statistics, Armonk, NY) software. Results: A total of 582 patients, 342 (58.8%) female and 240 (41.2%) male, were included in our study. Of the patients included in the study, 290 (49.8%) were diagnosed with ankylosing spondylitis (AS), 213 (36.6%) rheumatoid arthritis (RA), and 23 (4%) psoriatic arthritis (PsA). HBsAg 1.4%, Anti-HBs 51.7%, Anti-HBc IgG 31.4% and Anti-HCV 0.3% were positive. Looking according to the diagnosis; In AS; HBsAg 1.7%, Anti-HBs 53.1%, Anti-HBc IgG 38.9%, Anti-HCV 0.0%, in RA; HBsAg was 1.4%, Anti-HBs 51.9%, Anti-HBc IgG 41.7%, Anti-HCV 0.5% were detected. Conclusion: In our country, HBV and HCV infections are still seen at medium endemic levels. Since biological treatments may cause reactivation of HBV and HCV infections, screening, prophylaxis and treatment of these infections before biological treatment still maintains its importance.
topic hepatitis b
hepatitis c
biological therapy.
url http://diclemedj.org/upload/sayi/79/Dicle%20Med%20J-04421.pdf
work_keys_str_mv AT mehmetalibalcı hbvandhcvseroprevalenceinrheumatologypatientsusingbiologicaldrugs
AT nazımekin hbvandhcvseroprevalenceinrheumatologypatientsusingbiologicaldrugs
_version_ 1724364340232978432